The article discusses Bio-Techne Corporation's Q4 performance, highlighting the impact of NIH funding cuts and tariffs on its business. It includes stock data, market cap, and financial metrics, with a focus on the company's position in the life science market.

TD Cowen analyst Daniel Brennan initiated a Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target, citing undervaluation and growth potential in life science tools. The analyst highlights the company's strong portfolio, margin expansion prospects, and resilience amid macroeconomic risks.

The article analyzes Bio-Techne Corporation's high price-to-earnings (P/E) ratio of 70x, which is higher than most U.S. companies, but attributes it to expected earnings growth. Despite a 35% decline in earnings last year and a 42% cumulative decline over three years, analysts forecast 34% annual EPS growth, outpacing the broader market's 11% growth. Shareholders remain confident in the company's future, though risks are noted.

The article presents a discounted cash flow (DCF) analysis of Bio-Techne Corporation (NASDAQ:TECH), estimating its intrinsic value at $61.27 using a 2-stage growth model. The current share price of $58.78 is considered close to fair value, with an analyst target of $66.00 (7.7% above the estimated fair value). The analysis includes 10-year free cash flow projections, terminal value calculations, and assumptions about growth rates and discount rates.

The global thermal cycler market is projected to grow from USD 1.15 billion in 2025 to USD 2.39 billion by 2034, driven by AI integration, PCR advancements, and demand in healthcare, biotechnology, and research. Key segments include real-time PCR, digital PCR, and gradient PCR, with North America, Asia Pacific, and Europe as major regions.